Previous 10 | Next 10 |
2023-06-26 06:51:33 ET Shares of Biomea Fusion ( NASDAQ: BMEA ) gained ~19% pre-market Monday as Wall Street reacted to the latest data from the company’s ongoing Phase 1/2 clinical study for lead asset BMF-219 in adults with uncontrolled type 2 diabetes. 12-week data...
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B, measured during oral glucose tolerance testing (OGTT), supporting improved beta cell function for these patients Observations of durable and...
2023-06-23 21:00:44 ET Barclays says it has chosen Biomea Fusion ( NASDAQ: BMEA ), Replimune ( NASDAQ: REPL ), Syndax Pharmaceuticals ( NASDAQ: SNDX ) and Iovance Biotherapeutics ( NASDAQ: IOVA ) as its top picks in the small and mid-cap oncology space for th...
New clinical data from COVALENT-111 will be unveiled during a late-breaking poster presentation at ADA’s Scientific Sessions BMF-219, an orally delivered novel covalent menin inhibitor, is designed to regenerate, preserve, and reactivate healthy, insulin-producing beta cells Biom...
2023-05-28 07:57:54 ET Summary BMEA develops oral covalent small molecules for cancer and diabetes. Its lead asset is a menin inhibitor. While menin is a target in cancer, BMEA has successfully targeted it for diabetes. Biomea ( BMEA ) is a clinical stage company...
2023-05-12 10:58:46 ET More on Biomea Fusion Biomea Fusion up 9% on FDA IND application for leukemia candidate Biomea Fusion gains on upcoming data for lead asset For further details see: Biomea Fusion overweight at Barclays on covalent drug t...
2023-05-12 10:12:44 ET ARS Pharma ( NASDAQ: SPRY ) is up 85% in Friday morning trading after a panel of US FDA advisors late Thursday endorsed the company's epinephrine nasal spray candidate neffy. If approved , neffy would be the first epinephrine product to treat sev...
2023-05-02 17:22:05 ET Biomea Fusion press release ( NASDAQ: BMEA ): Q1 GAAP EPS of -$0.98 misses by $0.17 . Closed public offering of common stock with gross proceeds of $172.5 million, together with final cash balance of $86.7 million at end of first quarter of 2023,...
Reported initial positive clinical data from first two cohorts of Phase II of ongoing Phase I/II study (COVALENT-111) of BMF-219, Biomea’s lead investigational, orally administered covalent menin inhibitor, as a novel, potentially disease-modifying treatment for patients with type 2 diabet...
BMF-500, a novel 3 rd generation covalent inhibitor of fms-like tyrosine kinase 3 (FLT3), is the second investigational compound, discovered and developed by Biomea’s FUSION™ System, to advance to the clinic. Phase I study (COVALENT-103) of BMF-500 will examine its safety an...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA). Investors who purchased Biomea securities are encouraged to obtain additional information...